NCT00971308View on ClinicalTrials.gov

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Chronic Hepatitis C
Interventions
DRUG

BMS-824393

Capsule, Oral, 50mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule, Oral, 100mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule, Oral, 10mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule. Oral, 1mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days

Trial Locations (6)

21225

Parexel International - Baltimore Epcu, Baltimore

32809

Orlando Clinical Research Center, Orlando

33169

Elite Research Institute, Miami

78215

Alamo Medical Research, San Antonio

90630

West Coast Clinical Trials, Llc, Cypress

92801

Advanced Clinical Research Institute, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY